Selected article for: "age year and syncytial virus"

Author: Jartti, Tuomas; Smits, Hermelijn H.; Bønnelykke, Klaus; Bircan, Ozlem; Elenius, Varpu; Konradsen, Jon R.; Maggina, Paraskevi; Makrinioti, Heidi; Stokholm, Jakob; Hedlin, Gunilla; Papadopoulos, Nikolaos; Ruszczynski, Marek; Ryczaj, Klaudia; Schaub, Bianca; Schwarze, Jürgen; Skevaki, Chrysanthi; Stenberg-Hammar, Katarina; Feleszko, Wojciech
Title: Bronchiolitis needs a revisit: Distinguishing between virus entities and their treatments
  • Document date: 2018_11_25
  • ID: 4svg09dt_50
    Snippet: F I G U R E 5 Major factors influencing asthma risk in young children suffering from bronchiolitis. RV, rhinovirus; RSV, respiratory syncytial virus; n-3 LCPUFA, n-3 (omega-3) long-chain polyunsaturated fatty acids Going forward, it will be important to identify the patients at high risk of asthma and to find the specific primary and secondary prevention strategies for each individual patient ( Figure 5 ), for example, sensitization, eczema, and .....
    Document: F I G U R E 5 Major factors influencing asthma risk in young children suffering from bronchiolitis. RV, rhinovirus; RSV, respiratory syncytial virus; n-3 LCPUFA, n-3 (omega-3) long-chain polyunsaturated fatty acids Going forward, it will be important to identify the patients at high risk of asthma and to find the specific primary and secondary prevention strategies for each individual patient ( Figure 5 ), for example, sensitization, eczema, and the first severe wheeze caused by RV appear to predict atopic asthma, while the first severe wheeze before 1-year age, RV/RSV-negative etiology, and/or association with parental smoking appear to predict nonatopic asthma. 7 In conclusion, these new insights into viral virulence, personal risk factors (genetics, allergy, and antiviral immunity), and environmental exposures (farm, urban, microbes, and nutrition) provide hope that in future we might be able to reduce the occurrence of childhood asthma ( Figure 5 ).

    Search related documents:
    Co phrase search for related documents
    • antiviral immunity and fatty acid: 1, 2
    • antiviral immunity and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • antiviral immunity and new insight: 1, 2
    • antiviral immunity and patient identify: 1
    • antiviral immunity and respiratory syncytial virus: 1, 2, 3, 4, 5, 6, 7
    • antiviral immunity and risk factor: 1
    • antiviral immunity and syncytial virus: 1, 2, 3, 4, 5, 6, 7
    • antiviral immunity and viral virulence: 1
    • asthma high risk and atopic asthma: 1, 2, 3, 4, 5
    • asthma high risk and childhood asthma: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • asthma high risk and environmental exposure: 1
    • asthma high risk and fatty acid: 1
    • asthma high risk and high risk: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53
    • asthma high risk and individual patient: 1
    • asthma high risk and nonatopic asthma: 1
    • asthma high risk and respiratory syncytial virus: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • asthma high risk and risk factor: 1, 2, 3, 4, 5, 6, 7
    • asthma high risk and secondary primary prevention: 1
    • asthma high risk and severe wheeze: 1